Llwytho...
P01.116 Treatment with Dabrafenib in a patient with BRAF mutated recurrent ganglioglioma
BACKGROUND: Gangliogliomas are rare tumor usually arising in the supratentorial region, WHO grade 1 or 2. In these tumors, BRAF mutation may constitute a driver genetic alteration and a biomarker of response to BRAF inhibitors. Dabrafenib is an oral inhibitor of BRAF and has shown to significantly i...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Neuro Oncol |
|---|---|
| Prif Awduron: | , , , , , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Oxford University Press
2018
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6144130/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy139.158 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|